577 related articles for article (PubMed ID: 23208490)
1. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
3. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Kobayashi N; Shimamura T; Tokuhisa M; Goto A; Endo I; Ichikawa Y
Medicine (Baltimore); 2017 May; 96(19):e6769. PubMed ID: 28489753
[TBL] [Abstract][Full Text] [Related]
4. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
7. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
9. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Ychou M; Conroy T; Seitz JF; Gourgou S; Hua A; Mery-Mignard D; Kramar A
Ann Oncol; 2003 Mar; 14(3):481-9. PubMed ID: 12598357
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
11. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
12. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
[TBL] [Abstract][Full Text] [Related]
13. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
[TBL] [Abstract][Full Text] [Related]
14. A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.
Chiesa MD; Buti S; Tomasello G; Negri F; Buononato M; Brunelli A; Lazzarelli S; Brighenti M; Donati G; Passalacqua R
Tumori; 2007; 93(3):244-7. PubMed ID: 17679458
[TBL] [Abstract][Full Text] [Related]
15. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A; Li CP; Bodoky G; Dean A; Shan YS; Jameson G; Macarulla T; Lee KH; Cunningham D; Blanc JF; Hubner RA; Chiu CF; Schwartsmann G; Siveke JT; Braiteh F; Moyo V; Belanger B; Dhindsa N; Bayever E; Von Hoff DD; Chen LT;
Lancet; 2016 Feb; 387(10018):545-557. PubMed ID: 26615328
[TBL] [Abstract][Full Text] [Related]
16. [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].
Song Y; Li WW; Huang J
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):380-383. PubMed ID: 28535657
[No Abstract] [Full Text] [Related]
17. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
19. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
20. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]